DBV Technologies : Ordinary and Extraordinary General Meeting of June 15, 2017 Procedures for Obtaining Preparatory Documents for the General Meeting
(Thomson Reuters ONE) -
AMF REGULATED INFORMATION
Montrouge, France, May 24, 2017
Ordinary and Extraordinary General Meeting of June 15, 2017
Procedures for Obtaining Preparatory Documents for the General Meeting
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - NASDAQ: DBVT) announced
today that it will hold its Ordinary and Extraordinary General Meeting on June
15, 2017 at 8:30 a.m. CEST at the Company's headquarters located at 177-181
Avenue Pierre Brossolette - 92120 Montrouge, France.
The notice (l'avis préalable) containing the detailed agenda, draft resolutions
as well as instructions to participate and vote for this meeting was published
in the French official legal announcement publication "Direction de
l'Information Légale et Administrative (DILA), Bulletin des Annonces Légales
Obligatoires (BALO)" dated May 10, 2017. The convening notice for shareholders
(l'avis de convocation) stating the time and place of the meeting will be
published in the BALO dated May 31, 2017 and in the Legal Gazette on May
31, 2017.
The preparatory documents for the General Meeting listed in article R. 225-73-1
of the French Commercial Code are posted on the Investor Relations section of
the Company's website located at: http://www.dbvtechnologies.com/en/investor-
relations/general-meeting.
The documents for the General Meeting will also be made available to
shareholders as of the date of the convening notice is issued. Thus, in
accordance with applicable law and regulations:
* Any shareholder holding registered shares may, until the fifth day prior to
the General Meeting, request that the Company send them the documents
required under articles L.225-115 and R.225-83 of the French Commercial
Code, electronically at their express request. For shareholders holding
bearer shares, the exercise of this right is subject to the submission of a
certificate of participation in the bearer share accounts held by the
authorized financial intermediary.
* Any shareholder may consult the documents and information referred to in
articles L.225-115 and R.225-83 of the French Commercial Code, which are
available at the Company's headquarters.
About DBV Technologies
DBV Technologies is developing Viaskin®, a proprietary technology platform with
broad potential applications in immunotherapy. Viaskin is based on epicutaneous
immunotherapy, or EPIT®, DBV's method of delivering biologically active
compounds to the immune system through intact skin. With this new class of self-
administered and non-invasive product candidates, the company is dedicated to
safely transforming the care of food allergic patients, for whom there are no
approved treatments. DBV's food allergies programs include ongoing clinical
trials of Viaskin Peanut and Viaskin Milk, and preclinical development of
Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of
Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring
potential applications of its platform in vaccines and other immune diseases.
DBV Technologies has global headquarters in Montrouge, France and New York, NY.
Company shares are traded on segment A of Euronext Paris (Ticker: DBV, ISIN
code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global
Select Market in the form of American Depositary Shares (each representing one-
half of one ordinary share) (Ticker: DBVT). For more information on DBV
Technologies, please visit our website: www.dbv-technologies.com
DBV Technologies Contact
Sara Blum Sherman
Director, Investor Relations
+1 212-271-0740
sara.sherman(at)dbv-technologies.com
Media Contact
Andrea Fassacesia, Weber Shandwick
+1 212-445-8144
afassacesia(at)webershandwick.com
Media Contact Europe
Caroline Carmagnol, Alize RP, Relations Presse
+33 (0)6 64 18 99 59
caroline(at)alizerp.com
PDF version:
http://hugin.info/156437/R/2107679/800476.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: DBV Technologies via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 24.05.2017 - 22:30 Uhr
Sprache: Deutsch
News-ID 544499
Anzahl Zeichen: 4880
contact information:
Town:
Bagneux
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 195 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DBV Technologies : Ordinary and Extraordinary General Meeting of June 15, 2017 Procedures for Obtaining Preparatory Documents for the General Meeting"
steht unter der journalistisch-redaktionellen Verantwortung von
DBV Technologies (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
